What is/are Insulin aspart?
A fast acting insulin analog (marketed by Novo Nordisk as "NovoLog/NovoRapid") is a man-made form of human insulin. A single amino acid has been slightly changed in its molecular structure. This change helps the fast-acting insulin analog be absorbed quickly into the bloodstream. As a result, it starts working in minutes, which allows one to take insulin and eat right away. Fast-acting insulin analogs are considered to act similarly to the way insulin is released in people without diabetes mellitus.
Novolog allows for a flexible dosing schedule, which allows patients to adjust their insulin according to any changes in their eating habits. The safety and efficacy of Insulin aspart (NovoLog/NovoRapid) in real-life clinical practice was evaluated in the A1chieve study.
It was created through recombinant DNA technology so that the amino acid, B28, which is normally proline, is substituted with an aspartic acid residue. This analog has increased charge repulsion, which prevents the formation of hexamers, to create a faster-acting insulin. The sequence was inserted into the yeast genome, and the yeast expressed the insulin analog, which was then harvested from a bioreactor. According to JDRF, insulin aspart was approved for marketing in the United States by the Food and Drug Administration in June 2000.
Insulin aspart can be used in CSII pumps and Flexpen, Novopen delivery devices for subcutaneous injection. Additionally, it can be used with an injection port such as the I-port.
Novolog® is used for the treatment of patients with diabetes mellitus to control hyperglycemia. Novolog® has a more rapid onset, and a shorter duration of activity than normal human insulin. Therefore, Novolog® given by injection should normally be used in a regimen with long-acting or intermediate insulin. Novolog® can also be used with external insulin pumps. The insulin should be changed in the reservoir of the insulin pump at least every 6 days, and the infusion sets should be changed at least every 3 days. The following insulin pumps have been used in Novolog® clinical or in vitro studies conducted by Novo Nordisk: Medtronic Paradigm® 512 and 712, Minimed 508, Disetronic® D-TRON® and H-TRON®.
The safety of Novolog in patients with diabetes has been evaluated in several clinical studies. Novolog was compared with regular human insulin, and there was no difference in the frequency of adverse effects between the two treatments. The side effects that are commonly associated with insulin therapy include: allergic reactions, injection site irritation, rashes, and hypoglycemia. The most common side effect is hypoglycemia. Long-term use of insulin, including Novolog®, can cause lipodystrophy at the site of repeated injections or infusion. To reduce the risk of lipodystrophy, rotate the injection sites within the same region. Weight gain can also occur with the use of Novolog® and it has been attributed to anabolic effects of insulin and a decrease in glucosuria. Use of Novolog® has also been associated with sodium retention and edema.
This article uses material from the Wikipedia article Insulin aspart, which is released under the Creative Commons Attribution-Share-Alike License 3.0.